Evidence-Based Treatment for Uveitis
- PMID: 31507124
Evidence-Based Treatment for Uveitis
Abstract
Uveitis is an inflammatory disorder of the uveal tract of the eye that can affect both adults and children. Non-infectious uveitis can be an expression of a systemic autoimmune condition, or it can be idiopathic. It is a serious disease, associated with possible severe complications leading to visual impairment and blindness. For this reason, a prompt diagnosis and assessment of an appropriate treatment, with the collaboration of specialists such as ophthalmologists and rheumatologists, are extremely important. Many treatment options may be associated to side effects; therefore, clinicians should follow a stepladder approach starting with the least aggressive treatments to induce remission of inflammation. In this review, we reported the current evidence-based treatments for non-infectious uveitis in pediatric and adult patients with particular attention to the biologic response modifier treatment options. Important multicenter studies have demonstrated the efficacy of adalimumab, both in adults (VISUAL I, VISUAL II, VISUAL III) and in children (SYCAMORE, ADJUVITE), while for other agents data are still scarce.
Similar articles
-
A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.Expert Opin Pharmacother. 2014 Oct;15(15):2141-54. doi: 10.1517/14656566.2014.948417. Expert Opin Pharmacother. 2014. PMID: 25226529 Review.
-
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.Lancet. 2016 Sep 17;388(10050):1183-92. doi: 10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16. Lancet. 2016. PMID: 27542302 Clinical Trial.
-
Treatment strategies for childhood noninfectious chronic uveitis: an update.Expert Opin Investig Drugs. 2012 Jan;21(1):1-6. doi: 10.1517/13543784.2012.636350. Epub 2011 Nov 11. Expert Opin Investig Drugs. 2012. PMID: 22074394 Review.
-
[Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy].Ophthalmologe. 2016 May;113(5):391-7. doi: 10.1007/s00347-016-0262-4. Ophthalmologe. 2016. PMID: 27142035 Review. German.
-
Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.Ophthalmology. 2018 Sep;125(9):1444-1451. doi: 10.1016/j.ophtha.2018.02.020. Epub 2018 Mar 27. Ophthalmology. 2018. PMID: 29602570 Clinical Trial.
Cited by
-
Contrast Sensitivity Deficits and Its Structural Correlates in Fuchs Uveitis Syndrome.Front Med (Lausanne). 2022 May 19;9:850435. doi: 10.3389/fmed.2022.850435. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35665328 Free PMC article.
-
Sirolimus-Loaded Intravitreal Implant for Effective Treatment of Experimental Uveitis.AAPS PharmSciTech. 2021 Jan 6;22(1):35. doi: 10.1208/s12249-020-01898-4. AAPS PharmSciTech. 2021. PMID: 33404988
-
Demography and clinical pattern of newly diagnosed uveitis patients in Malaysia.J Ophthalmic Inflamm Infect. 2022 Sep 1;12(1):28. doi: 10.1186/s12348-022-00306-1. J Ophthalmic Inflamm Infect. 2022. PMID: 36048269 Free PMC article.
-
Uveitis in the Pediatric Population and Therapeutic Management: A Current Literature Review.Children (Basel). 2024 Jun 25;11(7):769. doi: 10.3390/children11070769. Children (Basel). 2024. PMID: 39062219 Free PMC article. Review.
-
Chronic Uveitis in Children.Indian J Pediatr. 2022 Apr;89(4):358-363. doi: 10.1007/s12098-021-03884-5. Epub 2021 Nov 3. Indian J Pediatr. 2022. PMID: 34731440